Asset profile
YN001
Protein / enzyme therapeutic
Evidence outlook · no controlled comparison
NCT06048588 · Atherosclerotic Cardiovascular Disease
The lead study's design has limits that temper confidence (see the rationale below), and it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT06048588: The study randomized 144 participants and used triple blinding with placebo and an active rosuvastatin comparator, but it was an early-phase dose-escalation study whose primary measures were safety and pharmacokinetics rather than a clinical outcome. Because no results are posted, whether any primary endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 60 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| YN001: this drug | Phase 2 | Protein / enzyme therapeutic | CD44; HMG-CoA reductase | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lomitapide (Juxtapid) | Approved | Small molecule | MTP | ||
| Nexlizet | Approved | — | — | ||
| Olezarsen (Tryngolza) | Approved | RNA / oligonucleotide | APOC3 | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
July 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.